期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
Noncoding RNAs in cancer and cancer stem cells 被引量:11
1
作者 Tianzhi Huang Angel Alvarez +1 位作者 Bo Hu Shi-Yuan Cheng 《Chinese Journal of Cancer》 SCIE CAS CSCD 2013年第11期582-593,共12页
In recent years, it has become increasingly apparent that noncoding RNAs(ncRNA) are of crucial importance for human cancer. The functional relevance of ncRNAs is particularly evident for microRNAs(miRNAs) and long non... In recent years, it has become increasingly apparent that noncoding RNAs(ncRNA) are of crucial importance for human cancer. The functional relevance of ncRNAs is particularly evident for microRNAs(miRNAs) and long noncoding RNAs(lncRNAs). miRNAs are endogenously expressed small RNA sequences that act as post-transcriptional regulators of gene expression and have been extensively studied for their roles in cancers, whereas lncRNAs are emerging as important players in the cancer paradigm in recent years. These noncoding genes are often aberrantly expressed in a variety of human cancers. However, the biological functions of most ncRNAs remain largely unknown. Recently, evidence has begun to accumulate describing how ncRNAs are dysregulated in cancer and cancer stem cells, a subset of cancer cells harboring self-renewal and differentiation capacities. These studies provide insight into the functional roles that ncRNAs play in tumor initiation, progression, and resistance to therapies, and they suggest ncRNAs as attractive therapeutic targets and potentially useful diagnostic tools. 展开更多
关键词 非编码RNA 干细胞 癌症 MIRNA RNA序列 生物学功能 微RNA 基因表达
下载PDF
Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models
2
作者 Alice Drobny Fanni Annamária Boros +9 位作者 Denise Balta Susy Prieto Huarcaya Deniz Caylioglu Niyeti Qazi Julia Vandrey Yanni Schneider Jan Philipp Dobert Caleb Pitcairn Joseph Robert Mazzulli Friederike Zunke 《Translational Neurodegeneration》 CSCD 2023年第1期479-499,共21页
Background Lysosomal dysfunction has been implicated in a number of neurodegenerative diseases such as Parkinson’s disease(PD).Various molecular,clinical and genetic studies have highlighted a central role of lysosom... Background Lysosomal dysfunction has been implicated in a number of neurodegenerative diseases such as Parkinson’s disease(PD).Various molecular,clinical and genetic studies have highlighted a central role of lysosomal pathways and proteins in the pathogenesis of PD.Within PD pathology the synaptic protein alpha-synuclein(αSyn)converts from a soluble monomer to oligomeric structures and insoluble amyloid fibrils.The aim of this study was to unravel the effect ofαSyn aggregates on lysosomal turnover,particularly focusing on lysosomal homeostasis and cathepsins.Since these enzymes have been shown to be directly involved in the lysosomal degradation ofαSyn,impairment of their enzymatic capacity has extensive consequences.Methods We used patient-derived induced pluripotent stem cells and a transgenic mouse model of PD to examine the effect of intracellularαSyn conformers on cell homeostasis and lysosomal function in dopaminergic(DA)neurons by biochemical analyses.Results We found impaired lysosomal trafficking of cathepsins in patient-derived DA neurons and mouse models withαSyn aggregation,resulting in reduced proteolytic activity of cathepsins in the lysosome.Using a farnesyltransferase inhibitor,which boosts hydrolase transport via activation of the SNARE protein ykt6,we enhanced the maturation and proteolytic activity of cathepsins and thereby decreasedαSyn protein levels.Conclusions Our findings demonstrate a strong interplay betweenαSyn aggregation pathways and function of lysosomal cathepsins.It appears thatαSyn directly interferes with the enzymatic function of cathepsins,which might lead to a vicious cycle of impairedαSyn degradation. 展开更多
关键词 Dopaminergic neurons iPSC-derived models LYSOSOME Parkinson’s disease Protein trafficking SYNUCLEINOPATHY
原文传递
DNA damage and metabolic mechanisms of cancer drug resistance 被引量:1
3
作者 Deanna Tiek Shi-Yuan Cheng 《Cancer Drug Resistance》 2022年第2期368-379,共12页
Cancer drug resistance is one of the main barriers to overcome to ensure durable treatment responses.While many pivotal advances have been made in first combination therapies,then targeted therapies,and now broadening... Cancer drug resistance is one of the main barriers to overcome to ensure durable treatment responses.While many pivotal advances have been made in first combination therapies,then targeted therapies,and now broadening out to immunomodulatory drugs or metabolic targeting compounds,drug resistance is still ultimately universally fatal.In this brief review,we will discuss different strategies that have been used to fight drug resistance from synthetic lethality to tumor microenvironment modulation,focusing on the DNA damage response and tumor metabolism both within tumor cells and their surrounding microenvironment.In this way,with a better understanding of both targetable mutations in combination with the metabolism,smarter drugs may be designed to combat cancer drug resistance. 展开更多
关键词 METABOLISM DAMAGE DRUGS
原文传递
Tumor microenvironment signaling and therapeutics in cancer progression 被引量:5
4
作者 Anshika Goenka Fatima Khan +5 位作者 Bhupender Verma Priyanka Sinha Crismita C.Dmello Manasi PJogalekar Prakash Gangadaran Byeong-Cheol Ahn 《Cancer Communications》 SCIE 2023年第5期525-561,共37页
Tumor development and metastasis are facilitated by the complex interactions between cancer cells and theirmicroenvironment,which comprises stromal cells and extracellular matrix(ECM)components,among other factors.Str... Tumor development and metastasis are facilitated by the complex interactions between cancer cells and theirmicroenvironment,which comprises stromal cells and extracellular matrix(ECM)components,among other factors.Stromal cells can adopt new phenotypes to promote tumor cell invasion.Adeep understanding of the signaling pathways involved in cell-to-cell and cell-to-ECM interactions is needed to design effective intervention strategies that might interrupt these interactions.In this review,we describe the tumor microenvironment(TME)components and associated therapeutics.We discuss the clinical advances in the prevalent and newly discovered signaling pathways in the TME,the immune checkpoints and immunosuppressive chemokines,and currently used inhibitors targeting these pathways.These include both intrinsic and non-autonomous tumor cell signaling pathways in the TME:protein kinase C(PKC)signaling,Notch,and transforming growth factor(TGF-β)signaling,Endoplasmic Reticulum(ER)stress response,lactate signaling,Metabolic reprogramming,cyclic GMP–AMP synthase(cGAS)–stimulator of interferon genes(STING)and Siglec signaling pathways.We also discuss the recent advances in Programmed Cell Death Protein 1(PD-1),Cytotoxic T-Lymphocyte Associated Protein 4(CTLA4),T-cell immunoglobulin mucin-3(TIM-3)and Lymphocyte Activating Gene 3(LAG3)immune checkpoint inhibitors along with the C-C chemokine receptor 4(CCR4)-C-C class chemokines 22(CCL22)/and 17(CCL17),C-C chemokine receptor type 2(CCR2)-chemokine(C-Cmotif)ligand 2(CCL2),C-C chemokine receptor type 5(CCR5)-chemokine(C-C motif)ligand 3(CCL3)chemokine signaling axis in the TME.In addition,this review provides a holistic understanding of the TME as we discuss the three-dimensional and microfluidic models of the TME,which are believed to recapitulate the original characteristics of the patient tumor and hence may be used as a platform to study new mechanisms and screen for various anti-cancer therapies.We further discuss the systemic influences of gut microbiota in TME reprogramming and treatment response.Overall,this review provides a comprehensive analysis of the diverse and most critical signaling pathways in the TME,highlighting the associated newest and critical preclinical and clinical studies along with their underlying biology.We highlight the importance of the most recent technologies of microfluidics and lab-on-chip models for TME research and also present an overview of extrinsic factors,such as the inhabitant human microbiome,which have the potential to modulate TME biology and drug responses. 展开更多
关键词 3D-model cancer therapy gut microbiota immune signaling METABOLISM SIGNALING tumor microenvironment
原文传递
隐源性卒中的心电监测策略:2015年卒中诊断和监测专题组的报告
5
作者 Gregory W. Albers Richard A. Bernstein +18 位作者 Johannes Brachmann John Camm J. Donald Easton Peter Fromm Shinya Goto Christopher B. Granger Stefan H. Hohnloser Elaine Hylek Amir K. Jaffer Derk W. Krieger Rod Passman Jesse M. Pines Shelby D. Reed Peter M. Rothwell Peter R. Kowey 地力木拉提·阿米提 朱沂 李红燕 牛晓珊 《国际脑血管病杂志》 2017年第7期592-600,共9页
卒中是一个重要的全球性公共卫生问题。2010年全世界总共发生3300万例卒中,其中1690万为首发卒中。卒中是仅次于心脏病的第二大全球人口死亡原因,占全部死亡的10%以上。卒中是一类异质性疾病,其病因可以是血管破裂(出血性)或血管... 卒中是一个重要的全球性公共卫生问题。2010年全世界总共发生3300万例卒中,其中1690万为首发卒中。卒中是仅次于心脏病的第二大全球人口死亡原因,占全部死亡的10%以上。卒中是一类异质性疾病,其病因可以是血管破裂(出血性)或血管闭塞(缺血性)。缺血性卒中约占全部卒中的85%,可根据发病机制进行分类。 展开更多
关键词 缺血性卒中 心电监测 隐源性 专题 诊断 公共卫生问题 死亡原因 异质性疾病
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部